U K
B U S I N E S S
P A R K
home page

The information below comes from the UK Activity Report.
Click here for further details

Zeneca Zeneca is planning a £5m extension at its pharmaceutical intermediates plant in Huddersfield, which will enable it to mix trial batches for customers and allow the main plant to focus entirely on bulk manufacture. 09-Apr-1999 Zeneca has won approval from the US Federal Trade Commission for its £21bn merger with Astra of Sweden. 26-Mar-1999 Zeneca has reached agreement with Monsanto that will enable it to market its Touchdown herbicide for use with Monsanto's genetically modified crops. 19-Mar-1999 Chiroscience has regained the rights for the Chirocaine anaesthetic from Zeneca, in order to clear the way for Zeneca to win approval for its merger with Astra. 02-Mar-1999 Zeneca is planning to invest £7.5m in new facilities at its Avonmouth plant, including a purification plant for its new anti-cholesterol drug. 17-Feb-1999 Zeneca is looking for a food industry partner to help with the launch of its Quorn meat substitute in the US. 11-Jan-1999 Zeneca has shortlisted three companies to buy its speciality chemicals division for up to £1.5bn - Bayer, BASF and Rohm & Haas - and a deal is expected within two months. 11-Jan-1999 Zeneca is to merge with Astra of Sweden in a £21bn deal, and the new group will have a London headquarters with the main R&D centre being in Sweden. 10-Dec-1998 Zeneca has put its speciality chemicals division up for sale in response to the sector's accelerating consolidation, and it could fetch more than £1bn. 13-Nov-1998 Zeneca is planning to cut 130 jobs over the next three years at its agrochemicals plant in Yalding, Kent. 04-Nov-1998 Zeneca has won US approval to sell Nolvadex, the world's first drug to prevent cancer. 30-Oct-1998 Zeneca is planning to expand its pharmaceutical headquarters in Alderley Park, Cheshire, with the creation of up to 300 jobs. 16-Oct-1998 Zeneca is investing £18m at its Macclesfield site in order to produce a potential treatment for cancer. 06-Oct-1998 Zeneca is expected to announce up to 200 jobs losses at its Huddersfield factory due to the loss of a major contract to supply textile dyes to BASF. 02-Oct-1998 Zeneca is to invest £50m in the development of new wheat varieties in collaboration with the John Innes Centre, and a new laboratory will be set up in Norwich. 17-Sep-1998 Zeneca has completed the acquisition of the pharmaceuticals business of Orica, formerly ICI Australia, for £117m. 05-Sep-1998 Zeneca is set to lose a multi-million-pound textile dyes contract from BASF, which could threaten jobs at its Huddersfield plant. 31-Aug-1998 Zeneca is building a £2m pilot fermentation plant at its Billingham site that will act as trouble-shooting facility in the manufacture of drugs. 25-Aug-1998 Zeneca has launched its Accolate oral preventative treatment for asthma into the UK market. 21-Jul-1998 Zeneca and Kvaerner are linking up with the Eversheds law firm to examine the possibility of launching the first pan-European pension fund, which they say has now become feasible following a recent ruling by the European Court of Justice. 26-May-1998 Chiroscience has announced a deal in which Zeneca will commercialise its Chirocaine anaesthetic, which should generate at least £200m of additional revenue for Chiroscience. 01-Apr-1998 Zeneca has been granted a US patent until 2015 for a new formulation of its Diprivan anaesthetic that is designed to cut the risk of accidental contamination of the drug. 04-Feb-1998 Zeneca is planning a £11m investment in the expansion of facilities to produce its Zomig migraine treatment, and a new plant will open in Macclesfield early next year. 06-Jan-1998 Zeneca is buying chlorothalonil, a leading fungicide, from ISK of Japan as well as the distribution rights to four other ISK products for a total £300m, in an effort to become on of the world's leading manufacturers of fungal control products. 18-Dec-1997 Zeneca has announced plans to double its drugs research output over the next five years in order to take 87 projects to the market. 02-Dec-1997 Zeneca has won US FDA approval to market Zomig, its migraine drug, in tablet form. 27-Nov-1997 Zeneca has won UK approval for Seroquel, a new schizophrenia drug. 05-Aug-1997 Zeneca is to acquire ICI Australia's pharmaceuticals business, for a price yet to be decided. 21-Jun-1997 Zeneca has won US approval for the use of its Abound fungicide on crops. 05-Jun-1997 Zeneca is linking up with Amersham International and Molecular Dynamics of the US to develop high-speed tests and reagents for gene analysis. 16-May-1997 Zeneca is acquiring Mogen International, the Dutch plant biotechnology concern, for £46m, and expects to benefit from Mogen's expertise in fungal control. 14-May-1997 Zeneca is to collaborate with Oxford University to identify genes that cause ischaemic heart disease. 30-Apr-1997 Zeneca has launched Zomig, a new migraine drug. 08-Apr-1997 Zeneca is to acquire the remaining 50% of Salick Healthcare, the US operator of outpatient clinics, for £147m. 29-Mar-1997 Zeneca and Xenova have reached agreement to jointly develop pharmaceuticals from natural compounds. 20-Mar-1997 Zeneca has won UK approval for Zomig, a new migraine drug which is expected to compete against Glaxo Wellcome's new Naramig drug. 12-Mar-1997 Zeneca has been warned by the US FDA that it must sort out problems with the sterile manufacturing area at its Macclesfield plant in order to gain approval for any new drug applications. 01-Mar-1997 Zeneca has made a licensing agreement with Pharmacopeia of the US in which Zeneca will have access to Pharmacopeia's library of molecules. 30-Jan-1997 Zeneca has won FDA approval to sell Kadian, a morphine-based pain relief drug, in capsule form in the US. 06-Jul-1996 The government has banned the use of Roseclear, Zeneca's garden pesticide, due to fears over potential eye damage. 28-Jun-1996 Zeneca has won US approval to sell its new Merrem antibiotic, which works against a wide range of bacteria. 25-Jun-1996 Zeneca has signed a deal with Incyte Pharmaceuticals of the US to give it access to genetics databases, at a cost of up to £7m a year. 18-Jun-1996 BASF is buying Zeneca's textile colours operation for up to £150m, which includes sites in Ellesmere Port, Brazil and North Carolina. 09-May-1996 Zeneca has sold its speciality inks business to Sun Chemical for £40m and is discussing the sale of its textile dyes operation. 08-Mar-1996 Glaxo Wellcome is to sell its 311C90 migraine drug to Zeneca to comply with competition requirements following the creation of the merged group. 09-Feb-1996 Zeneca is planning a major restructuring of its manufacturing and distribution, but job losses are unlikely to hit R&D. 24-Jan-1996 Zeneca has announced plans to boost drugs R&D and to develop alliances with biotechnology companies. 13-Dec-1995 Zeneca has won approval in the US for the heart attack drug Zestril. 30-Nov-1995 Zeneca and Celltech have signed a £10m deal to collaborate in cancer drug research. 10-Oct-1995 Zeneca has won preliminary US FDA approval for its cancer drug, Casodex. 20-Sep-1995 The information above comes from the UK Activity Report Copyright UK Business Park 1995-2007